The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Knowing the warning signs of dementia is important for dealing with the debilitating condition that currently has no cure.

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

Preserving levels of brain glucose metabolism can both slow cognitive decline and reduces the risk of conversion to dementia.

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...